Search

Your search keyword '"Di Meco, E."' showing total 7 results
Start Over Author "Di Meco, E." Database OAIster
7 results on '"Di Meco, E."'

1. Characterization of the PADME positron beam for the X17 measurement

Author

Bertelli, S., Bossi, F., Buonomo, B., De Sangro, R., Di Giulio, C., Di Meco, E., Dimitrova, K., Domenici, D., Ferrarotto, F., Finocchiaro, G., Foggetta, L. G., Frankenthal, A., Garattini, M., Georgiev, G., Gianotti, P., Ivanov, S., Ivanov, Sv., Kozhuharov, V., Leonardi, E., Long, E., Mancini, M., Organtini, G. C., Raggi, M., Sarra, I., Simeonov, R., Spadaro, T., Spiriti, E., Valente, P., Variola, A., Vilucchi, E., Bertelli, S., Bossi, F., Buonomo, B., De Sangro, R., Di Giulio, C., Di Meco, E., Dimitrova, K., Domenici, D., Ferrarotto, F., Finocchiaro, G., Foggetta, L. G., Frankenthal, A., Garattini, M., Georgiev, G., Gianotti, P., Ivanov, S., Ivanov, Sv., Kozhuharov, V., Leonardi, E., Long, E., Mancini, M., Organtini, G. C., Raggi, M., Sarra, I., Simeonov, R., Spadaro, T., Spiriti, E., Valente, P., Variola, A., and Vilucchi, E.

Abstract

This paper presents a detailed characterization of the positron beam delivered by the Beam Test Facility at Laboratori Nazionali of Frascati to the PADME experiment during Run III, which took place from October to December 2022. It showcases the methodology used to measure the main beam parameters such as the position in space, the absolute momentum scale, the beam energy spread, and its intensity through a combination of data analysis and Monte Carlo simulations. The results achieved include an absolute precision in the momentum of the beam to within $\sim$ 1-2 MeV$/c$, a relative beam energy spread below 0.25\%, and an absolute precision in the intensity of the beam at the level of 2\% percent.

Published
2024

2. Beam test, simulation, and performance evaluation of PbF$_2$ and PWO-UF crystals with SiPM readout for a semi-homogeneous calorimeter prototype with longitudinal segmentation

Author

Cantone, C., Carsi, S., Ceravolo, S., Di Meco, E., Diociaiuti, E., Frank, I., Kholodenko, S., Martellotti, S., Mirra, M., Monti-Guarnieri, P., Moulson, M., Paesani, D., Prest, M., Romagnoni, M., Sarra, I., Sgarbossa, F., Soldani, M., Vallazza, E., Cantone, C., Carsi, S., Ceravolo, S., Di Meco, E., Diociaiuti, E., Frank, I., Kholodenko, S., Martellotti, S., Mirra, M., Monti-Guarnieri, P., Moulson, M., Paesani, D., Prest, M., Romagnoni, M., Sarra, I., Sgarbossa, F., Soldani, M., and Vallazza, E.

Abstract

Crilin (Crystal Calorimeter with Longitudinal Information) is a semi-homogeneous, longitudinally segmented electromagnetic calorimeter based on high-$Z$, ultra-fast crystals with UV-extended SiPM readout. The Crilin design has been proposed as a candidate solution for both a future Muon Collider barrel ECAL and for the Small Angle Calorimeter of the HIKE experiment. As a part of the Crilin development program, we have carried out beam tests of small ($10\times10\times40$~mm$^3$) lead fluoride (PbF$_2$) and ultra-fast lead tungstate (PbWO$_4$, PWO) crystals with 120~GeV electrons at the CERN SPS to study the light yield, timing response, and systematics of light collection with a proposed readout scheme. For a single crystal of PbF$_2$, corresponding to a single Crilin cell, a time resolution of better than 25~ps is obtained for $>$3 GeV of deposited energy. For a single cell of \pwo, a time resolution of better than 45~ps is obtained for the same range of deposited energy. This timing performance fully satisfies the design requirements for the Muon Collider and HIKE experiments. Further optimizations of the readout scheme and crystal surface preparation are expected to bring further improvements.

Published
2023

3. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)

Author

Bai, F, Aldieri, C, Cattelan, A, Raumer, F, Di Meco, E, Moioli, M, Tordato, F, Morelli, P, Borghi, F, Rizzi, M, Van Hauwermeiren, E, Castelli, F, Migliorino, G, Menzaghi, B, Rizzardini, G, Saracino, A, Cascio, A, Puoti, M, d'Arminio Monforte, A, Marchetti, G, Bai F., Aldieri C., Cattelan A., Raumer F., Di Meco E., Moioli M. C., Tordato F., Morelli P., Borghi F., Rizzi M., Van Hauwermeiren E., Castelli F., Migliorino G., Menzaghi B., Rizzardini G., Saracino A., Cascio A., Puoti M., d'Arminio Monforte A., Marchetti G., Bai, F, Aldieri, C, Cattelan, A, Raumer, F, Di Meco, E, Moioli, M, Tordato, F, Morelli, P, Borghi, F, Rizzi, M, Van Hauwermeiren, E, Castelli, F, Migliorino, G, Menzaghi, B, Rizzardini, G, Saracino, A, Cascio, A, Puoti, M, d'Arminio Monforte, A, Marchetti, G, Bai F., Aldieri C., Cattelan A., Raumer F., Di Meco E., Moioli M. C., Tordato F., Morelli P., Borghi F., Rizzi M., Van Hauwermeiren E., Castelli F., Migliorino G., Menzaghi B., Rizzardini G., Saracino A., Cascio A., Puoti M., d'Arminio Monforte A., and Marchetti G.

Abstract

Objectives: We evaluated the efficacy and safety of dalbavancin in ABSSSI and ‘other sites’ infections’ (OTA). Methods: Observational study involving 11 Italian hospitals including patients that received ≥1 dose of dalbavancin in 2016–2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in a real-life setting. Results: 206 patients enrolled (males 50%, median age 62 [IQR 50–76] years), 60.2% ABSSSI, 39.8% OTA. 69.7% ABSSSI vs 90.7% OTA (p = 0.003) and 46.3% ABSSSI vs 37.2% OTA (p = 0.786) received previous and concomitant antibiotics, respectively. 82.5% reached clinical cure. Eleven (5.4%) patients had non-serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5–22 vs 3, 0–11.7; p<0.0001) and received longer previous (18 days, 9–30 vs 11, 7–19; p = 0.007)/concomitant antibiotic treatments (21 days, 14–52 vs 11, 8–14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed similar efficacy (85.5% vs 75%, p = 0.459) and safety (no AE: 81.5% vs 64.3%, p = 0.258); efficacy was independent of previous/concomitant therapies. Conclusions: Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.

Published
2020

4. HIKE, High Intensity Kaon Experiments at the CERN SPS

Author

Gil, E. Cortina, Jerhot, J., Lurkin, N., Numao, T., Velghe, B., Wong, V. W. S., Bryman, D., Bician, L., Hives, Z., Husek, T., Kampf, K., Koval, M., Akmete, A. T., Aliberti, R., Büscher, V., Di Lella, L., Doble, N., Peruzzo, L., Schott, M., Wahl, H., Wanke, R., Döbrich, B., Montalto, L., Rinaldi, D., Dettori, F., Cardini, A., Lai, A., Bomben, L., Carsi, S., Prest, M., Selmi, A., Lezzani, G., Monti-Guarnieri, P., Perna, L., Dalpiaz, P., Guidi, V., Mazzolari, A., Neri, I., Petrucci, F., Soldani, M., Bandiera, L., Ramusino, A. Cotta, Gianoli, A., Romagnoni, M., Sytov, A., Lenti, M., Panichi, I., Ruggiero, G., Bizzeti, A., Bucci, F., Antonelli, A., Di Meco, E., Lanfranchi, G., Martellotti, S., Martini, M., Moulson, M., Paesani, D., Sarra, I., Spadaro, T., Tinti, G., Vallazza, E., Ambrosino, F., Giordano, R., Massarotti, P., Napolitano, M., Saracino, G., Di Donato, C., D'Ambrosio, G., D'Errico, M., Mirra, M., Neshatpour, S., Fiorenza, R., Rosa, I., De Salvador, D., Sgarbossa, F., Anzivino, G., Germani, S., Volpe, R., Cenci, P., Cutini, S., Duk, V., Lubrano, P., Pepe, M., Piccini, M., Costantini, F., Donati, S., Giorgi, M., Giudici, S., Lamanna, G., Pedreschi, E., Pinzino, J., Sozzi, M., Fantechi, R., Giusti, V., Spinella, F., Mannelli, I., Raggi, M., Biagioni, A., Cretaro, P., Frezza, O., Cicero, F. Lo, Lonardo, A., Turisini, M., Vicini, P., Ammendola, R., Bonaiuto, V., Fucci, A., Salamon, A., Sargeni, F., Arcidiacono, R., Bloch-Devaux, B., Menichetti, E., Migliore, E., Biino, C., Marchetto, F., Baigarashev, D., Kambar, Y., Kereibay, D., Mukhamejanov, Y., Sakhiyev, S., Olvera, A. Briano, Engelfried, J., Estrada-Tristan, N., Piandani, R., Santos, M. A. Reyes, Rivera, K. A. Rodriguez, Boboc, P. C., Bragadireanu, A. M., Ghinescu, S. A., Hutanu, O. E., Blazek, T., Cerny, V., Kleimenova, A., Kucerova, Z., Santos, D. Martinez, Prouve, C., Boretto, M., Brizioli, F., Ceccucci, A., Corvino, M., Danielsson, H., Duval, F., Gamberini, E., Guida, R., Holzer, E. B., Jenninger, B., Miotto, G. Lehmann, Lichard, P., Massri, K., Minucci, E., Perrin-Terrin, M., Ryjov, V., Swallow, J., Van Dijk, M., Zamkovsky, M., Marchevski, R., Gerbershagen, A., Fry, J. R., Gonnella, F., Goudzovski, E., Henshaw, J., Kenworthy, C., Lazzeroni, C., Parkinson, C., Romano, A., Sanders, J., Shaikhiev, A., Tomczak, A., Heath, H., Britton, D., Norton, A., Protopopescu, D., Dainton, J. B., Jones, R. W. L., De Santo, A., Salvatore, F., Cooper, P., Coward, D., Rubin, P., Gil, E. Cortina, Jerhot, J., Lurkin, N., Numao, T., Velghe, B., Wong, V. W. S., Bryman, D., Bician, L., Hives, Z., Husek, T., Kampf, K., Koval, M., Akmete, A. T., Aliberti, R., Büscher, V., Di Lella, L., Doble, N., Peruzzo, L., Schott, M., Wahl, H., Wanke, R., Döbrich, B., Montalto, L., Rinaldi, D., Dettori, F., Cardini, A., Lai, A., Bomben, L., Carsi, S., Prest, M., Selmi, A., Lezzani, G., Monti-Guarnieri, P., Perna, L., Dalpiaz, P., Guidi, V., Mazzolari, A., Neri, I., Petrucci, F., Soldani, M., Bandiera, L., Ramusino, A. Cotta, Gianoli, A., Romagnoni, M., Sytov, A., Lenti, M., Panichi, I., Ruggiero, G., Bizzeti, A., Bucci, F., Antonelli, A., Di Meco, E., Lanfranchi, G., Martellotti, S., Martini, M., Moulson, M., Paesani, D., Sarra, I., Spadaro, T., Tinti, G., Vallazza, E., Ambrosino, F., Giordano, R., Massarotti, P., Napolitano, M., Saracino, G., Di Donato, C., D'Ambrosio, G., D'Errico, M., Mirra, M., Neshatpour, S., Fiorenza, R., Rosa, I., De Salvador, D., Sgarbossa, F., Anzivino, G., Germani, S., Volpe, R., Cenci, P., Cutini, S., Duk, V., Lubrano, P., Pepe, M., Piccini, M., Costantini, F., Donati, S., Giorgi, M., Giudici, S., Lamanna, G., Pedreschi, E., Pinzino, J., Sozzi, M., Fantechi, R., Giusti, V., Spinella, F., Mannelli, I., Raggi, M., Biagioni, A., Cretaro, P., Frezza, O., Cicero, F. Lo, Lonardo, A., Turisini, M., Vicini, P., Ammendola, R., Bonaiuto, V., Fucci, A., Salamon, A., Sargeni, F., Arcidiacono, R., Bloch-Devaux, B., Menichetti, E., Migliore, E., Biino, C., Marchetto, F., Baigarashev, D., Kambar, Y., Kereibay, D., Mukhamejanov, Y., Sakhiyev, S., Olvera, A. Briano, Engelfried, J., Estrada-Tristan, N., Piandani, R., Santos, M. A. Reyes, Rivera, K. A. Rodriguez, Boboc, P. C., Bragadireanu, A. M., Ghinescu, S. A., Hutanu, O. E., Blazek, T., Cerny, V., Kleimenova, A., Kucerova, Z., Santos, D. Martinez, Prouve, C., Boretto, M., Brizioli, F., Ceccucci, A., Corvino, M., Danielsson, H., Duval, F., Gamberini, E., Guida, R., Holzer, E. B., Jenninger, B., Miotto, G. Lehmann, Lichard, P., Massri, K., Minucci, E., Perrin-Terrin, M., Ryjov, V., Swallow, J., Van Dijk, M., Zamkovsky, M., Marchevski, R., Gerbershagen, A., Fry, J. R., Gonnella, F., Goudzovski, E., Henshaw, J., Kenworthy, C., Lazzeroni, C., Parkinson, C., Romano, A., Sanders, J., Shaikhiev, A., Tomczak, A., Heath, H., Britton, D., Norton, A., Protopopescu, D., Dainton, J. B., Jones, R. W. L., De Santo, A., Salvatore, F., Cooper, P., Coward, D., and Rubin, P.

Abstract

A timely and long-term programme of kaon decay measurements at a new level of precision is presented, leveraging the capabilities of the CERN Super Proton Synchrotron (SPS). The proposed programme is firmly anchored on the experience built up studying kaon decays at the SPS over the past four decades, and includes rare processes, CP violation, dark sectors, symmetry tests and other tests of the Standard Model. The experimental programme is based on a staged approach involving experiments with charged and neutral kaon beams, as well as operation in beam-dump mode. The various phases will rely on a common infrastructure and set of detectors., Comment: Letter of Intent submitted to CERN SPSC. Address all correspondence to hike-eb@cern.ch

Published
2022

5. Crilin: A CRystal calorImeter with Longitudinal InformatioN for a future Muon Collider

Author

Ceravolo, S., Colao, F., Curatolo, C., Di Meco, E., Diociaiuti, E., Lucchesi, D., Paesani, D., Pastrone, N., Saputi, A., Sarra, I., Sestini, L., Tagnani, D., Ceravolo, S., Colao, F., Curatolo, C., Di Meco, E., Diociaiuti, E., Lucchesi, D., Paesani, D., Pastrone, N., Saputi, A., Sarra, I., Sestini, L., and Tagnani, D.

Abstract

The measurement of physics processes at new energy frontier experiments requires excellent spatial, time, and energy resolutions to resolve the structure of collimated high-energy jets. In a future Muon Collider, the beam-induced backgrounds (BIB) represent the main challenge in the design of the detectors and of the event reconstruction algorithms. The technology and the design of the calorimeters should be chosen to reduce the effect of the BIB, while keeping good physics performance. Several requirements can be inferred: i) high granularity to reduce the overlap of BIB particles in the same calorimeter cell; ii) excellent timing (of the order of 100 ps) to reduce the out-of-time component of the BIB; iii) longitudinal segmentation to distinguish the signal showers from the fake showers produced by the BIB; iv) good energy resolution (less than 10%/sqrt(E)) to obtain good physics performance, as has been already demonstrated for conceptual particle flow calorimeters. Our proposal consists of a semi-homogeneous electromagnetic calorimeter based on Lead Fluoride Crystals (PbF2) readout by surface-mount UV-extended Silicon Photomultipliers (SiPMs): the Crilin calorimeter. In this paper, the performances of the Crilin calorimeter in the Muon Collider framework for hadron jets reconstruction have been analyzed. We report the single components characterizations together with the development of a small-scale prototype, consisting of 2 layers of 3x3 crystals each.

Published
2022
Full Text
View/download PDF

6. Procedura di assistenza ai pazienti diabetici nell’esperienza del Poliambulatorio Caritas di Roma; un approccio innovativo alla presa in carico della Cronicità in pazienti vulnerabili

Author

Mario Affronti, Manila Bonciani, Emanuela Forcella, Salvatore Geraci, Maurizio Marceca, Maria Laura Russo, Corsaro, Alice, Pettinicchio, V, Civitelli, G, Arrivi, F, Silvestrini, Giulia, Di Meco, Eugenia, Sciacca, S, Fratini, P, Geraci, S, Bruno, Stefania, Damiani, Gianfranco, Corsaro A, Silvestrini G, Di Meco E, Bruno S (ORCID:0000-0002-0362-4180), Damiani G (ORCID:0000-0003-3028-6188), Mario Affronti, Manila Bonciani, Emanuela Forcella, Salvatore Geraci, Maurizio Marceca, Maria Laura Russo, Corsaro, Alice, Pettinicchio, V, Civitelli, G, Arrivi, F, Silvestrini, Giulia, Di Meco, Eugenia, Sciacca, S, Fratini, P, Geraci, S, Bruno, Stefania, Damiani, Gianfranco, Corsaro A, Silvestrini G, Di Meco E, Bruno S (ORCID:0000-0002-0362-4180), and Damiani G (ORCID:0000-0003-3028-6188)

Published
2016

7. Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes

Author

Tumbarello, Mario, Trecarichi, Enrico Maria, Fiori, Barbara, Losito, Angela Raffaella, D'Inzeo, Tiziana, Campana, Lara, Ruggeri, A, Di Meco, E, Liberto, E, Fadda, G, Cauda, R, Spanu, T., Tumbarello, Mario (ORCID:0000-0002-9519-8552), Fiori, Barbara (ORCID:0000-0003-3318-5809), D'Inzeo, Tiziana (ORCID:0000-0003-1508-3518), Cauda, R (ORCID:0000-0002-1498-4229), Spanu, T. (ORCID:0000-0003-1864-5184), Tumbarello, Mario, Trecarichi, Enrico Maria, Fiori, Barbara, Losito, Angela Raffaella, D'Inzeo, Tiziana, Campana, Lara, Ruggeri, A, Di Meco, E, Liberto, E, Fadda, G, Cauda, R, Spanu, T., Tumbarello, Mario (ORCID:0000-0002-9519-8552), Fiori, Barbara (ORCID:0000-0003-3318-5809), D'Inzeo, Tiziana (ORCID:0000-0003-1508-3518), Cauda, R (ORCID:0000-0002-1498-4229), and Spanu, T. (ORCID:0000-0003-1864-5184)

Abstract

Our aims were to identify (i) risk factors associated with the acquisition of multidrug-resistant (MDR, to 3 or more classes of antimicrobials) Proteus mirabilis isolates responsible for bloodstream infections (BSIs) and (ii) the impact on mortality of such infections. Risk factors for acquiring MDR P. mirabilis BSIs were investigated in a case-case-control study; those associated with mortality were assessed by comparing survivors and nonsurvivors in a cohort study. The population consisted of 99 adult inpatients with P. mirabilis BSIs identified by our laboratory over an 11-year period (1999 to 2009), 36 (33.3%) of which were caused by MDR strains, and the overall 21-day mortality rate was 30.3%. Acquisition of an MDR strain was independently associated with admission from a long-term care facility (odds ratio [OR], 9.78; 95% confidence interval [CI], 1.94 to 49.16), previous therapy with fluoroquinolones (OR, 5.52; 95% CI, 1.30 to 23.43) or oxyimino-cephalosporins (OR, 4.72; 95% CI, 1.31 to 16.99), urinary catheterization (OR, 3.89; 95% CI, 1.50 to 10.09), and previous hospitalization (OR, 2.68; 95% CI, 10.4 to 6.89). Patients with MDR P. mirabilis BSIs received inadequate initial antimicrobial therapy (IIAT, i.e., treatment with drugs to which the isolate displayed in vitro resistance) more frequently than those with non-MDR infections; they also had increased mortality and (for survivors) longer post-BSI-onset hospital stays. In multivariate regression analysis, 21-day mortality was associated with septic shock at BSI onset (OR, 12.97; 95% CI, 32.2 to 52.23), P. mirabilis isolates that were MDR (OR, 6.62; 95% CI, 16.4 to 26.68), and IIAT (OR, 9.85; 95% CI, 26.7 to 36.25), the only modifiable risk factor of the 3. These findings can potentially improve clinicians' ability to identify P. mirabilis BSIs likely to be MDR, thereby reducing the risk of IIAT--a major risk factor for mortality in these cases--and facilitating the prompt implementation of appropriate in

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results